UTHR (United Therapeutics) Inventory Turnover: 0.74 (As of Mar. 2026)

What is United Therapeutics Inventory Turnover?

United Therapeutics UTHR +0.74% 88 Inventory Turnover is 0.74 as of Mar. 2026. GuruFocus rates UTHR with a GF Score™ of 88/100 and a GF Value™ of $386.38 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. United Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was $133 Mil. United Therapeutics's Average Total Inventories for the quarter that ended in Mar. 2026 was $181 Mil. United Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.74.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. United Therapeutics's Days Inventory for the three months ended in Mar. 2026 was 123.60.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. United Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.23.

United Therapeutics (NAS:UTHR) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

United Therapeutics's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2026 )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
	=	180.7	/	133.4	*	365 / 4
	=	123.60

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

United Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	180.7	/	781.5
	=	0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

United Therapeutics Inventory Turnover Related Terms

United Therapeutics Inventory Turnover Historical Data

* Premium members only.

The historical data trend for United Therapeutics's Inventory Turnover can be seen below:

United Therapeutics Inventory Turnover Chart

United Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Inventory Turnover

Get a 7-Day Free Trial

1.36

1.55

2.41

2.30

2.25

United Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Inventory Turnover	Get a 7-Day Free Trial															0.57	0.52	0.58	0.58	0.74

88GF Score

United Therapeutics Corp UTHR

Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

United Therapeutics Inventory Turnover Calculation

United Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

	Inventory Turnover (A: Dec. 2025 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2025 )	/ (	(Total Inventories (A: Dec. 2024 )	+	Total Inventories (A: Dec. 2025 ))	/	count )
=	384.4	/ (	(157.9	+	183.1)	/	2 )
=	384.4	/	170.5
=	2.25

United Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

	Inventory Turnover (Q: Mar. 2026 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Mar. 2026 )	/ (	(Total Inventories (Q: Dec. 2025 )	+	Total Inventories (Q: Mar. 2026 ))	/	count )
=	133.4	/ (	(183.1	+	178.3)	/	2 )
=	133.4	/	180.7
=	0.74

Frequently Asked Questions Learn more about Inventory Turnover →

What does a Inventory Turnover of 0.74 mean?

United Therapeutics (UTHR) has a Inventory Turnover of 0.74 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on United Therapeutics and its competitors.

Is United Therapeutics' Inventory Turnover too high?

United Therapeutics' current Inventory Turnover is 0.74. Overall, United Therapeutics has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does United Therapeutics' Inventory Turnover compare to VTRS and NBIX?

United Therapeutics' Inventory Turnover of 0.74 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Inventory Turnover for a Drug Manufacturers company?

A good Inventory Turnover depends on the Drug Manufacturers industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Inventory Turnover mean?

A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on United Therapeutics and its competitors. United Therapeutics's current Inventory Turnover is 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is United Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, United Therapeutics (UTHR) is currently considered Significantly Overvalued. The stock's GF Value™ is $386.38, compared to a current price of $545.85 — trading 41.3% above its estimated fair value. The current Inventory Turnover is 0.74. United Therapeutics' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Inventory Turnover calculated?

Inventory Turnover is calculated from a company's financial statements. For United Therapeutics (UTHR), the current Inventory Turnover is 0.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (UTHR) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of $545.85 is trading 41.3% above its estimated GF Value™ of $386.38. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for UTHR:

Inventory Turnover: 0.74
GF Value™: $386.38 vs. price of $545.85 (41.3% above fair value)
GF Score™: 88/100 with 7 warning signs

No single metric tells the full story. See the UTHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies VTRS NBIX ZTS ELAN ALKS HIMS LNTH LQDA AMRX INDV XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ HKSE:03692 NSE:DIVISLAB

Other Exchanges UTH:Germany U2TH34:Brazil

Address 1000 Spring Street, Silver Spring, MD, USA, 20910

Website https://www.unither.com

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

88GF Score

Get the complete analysis for UTHR

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$545.85

Price

$386.38

GF Value

View UTHR Analysis

See Inventory Turnover data for all stocks →